The Patent Finder

Zentiva K.S.

13 patents currently held · Updated Nov 17, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
7
Ending by 2030
Mar 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Apr 29, 2027
    The maintenance fee for Crystalline form of Canagliflozin and a method of its preparation (US 10,457,671) comes due Apr 29, 2027. Unpaid by Oct 29, 2027, it lapses early.
  • 1 fee due Jul 14, 2027
    The maintenance fee for Crystalline modifications of methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}phenyl)amino](phenyl)methylidene}-2-oxo-2,3-dihydro-1H-indole-6-carboxylate salts and methods of preparation thereof (US 10,532,981) comes due Jul 14, 2027. Unpaid by Jan 14, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 7,919,076PH-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,709,662Method of manufacturing (S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride (duloxetine)
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,034,807Salts of bazedoxifene
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,143,417Method for the preparation of zolmitriptan
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,394,961Method for the preparation of dabigatran
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,394,962Method for the preparation of dabigatran and its intermediates
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,603,990Grafted macromolecular conjugates of doxorubicin with anticancer activity and method of their preparation
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,779,005Salts of desvenlafaxine and a method of their preparation
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,862,723Stable polymorph of the salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-anime with L-tartaric acid
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,920,021Method of preparing vortioxetine
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 13 patents shown.
Pro members see all 13.
Pro members: see all 13 patents
Also on record, not counted in the 13: 1 patent in force now held by others · 7 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 abandoned · 1 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited